Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 1:334:129663.
doi: 10.1016/j.snb.2021.129663. Epub 2021 Feb 16.

Development of a SARS-CoV-2-derived receptor-binding domain-based ACE2 biosensor

Jung-Soo Suh  1 , Heon-Su Kim  1 , Tae-Jin Kim  1   2   3
Affiliations

Development of a SARS-CoV-2-derived receptor-binding domain-based ACE2 biosensor

Jung-Soo Suh et al. Sens Actuators B Chem. .

Abstract

The global outbreak of coronavirus disease and rapid spread of the causative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represent a significant threat to human health. A key mechanism of human SARS-CoV-2 infection is initiated by the combination of human angiotensin-converting enzyme 2 (hACE2) and the receptor-binding domain (RBD) of the SARS-CoV-2-derived spike glycoprotein. Despite the importance of these protein interactions, there are still insufficient detection methods to observe their activity at the cellular level. Herein, we developed a novel fluorescence resonance energy transfer (FRET)-based hACE2 biosensor to monitor the interaction between hACE2 and SARS-CoV-2 RBD. This biosensor facilitated the visualization of hACE2-RBD activity with high spatiotemporal resolutions at the single-cell level. Further studies revealed that the FRET-based hACE2 biosensors were sensitive to both exogenous and endogenous hACE2 expression, suggesting that they might be safely applied to the early stage of SARS-CoV-2 infection without direct virus use. Therefore, our novel biosensor could potentially help develop drugs that target SARS-CoV-2 by inhibiting hACE2-RBD interaction.

Keywords: ACE2; Biosensor; CQ, chloroquine; FRET; HCQ, hydroxychloroquine; Live-cell imaging; NA, numerical aperture; RBD, receptor-binding domain; RBM, receptor-binding motif; ROI, region of interest; SARS-CoV-2; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SEM, standard error of the mean; bg, background; hACE2, human angiotensin-converting enzyme 2.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Design and characterization of the FRET-based ACE2 biosensor. (a) Schematic diagram of the ACE2 biosensor. The ACE2 biosensor is composed of a YPet acceptor, SARS-CoV-2-derived RBD domain, and truncated Turquoise2-GL donor. The ACE2 biosensor mutants are E484 P (positive control) and F486 L (negative control). The ACE2-WT truncated membrane localization signal was inserted into the pmScarlet-I vector, and the ACE2-M82 K construct was developed as a negative control. (b) The ACE2 biosensor shows the conformational change by binding to ACE2, leading to an increase in the FRET ratio. This diagram was produced by Biorender (http://biorender.com/) (c) The normalized FRET/CFP emission ratios of the ACE2 biosensors (WT, E484 P, and F486 L) in HEK293 T cells co-transfected with ACE2-WT, ACE2-M82 K, or control pmScarlet-I vector (****p < 0.0001).
Fig. 2
Fig. 2
Dynamic visualization of the ACE2 biosensor in response to the ACE2 inhibitor. (a) Time-lapse FRET/CFP ratio images of the ACE2 biosensors (WT, E484 P, and F486 L) in HEK293 T cells co-transfected with control, ACE2-WT, or ACE2-M82 K treated with 100 μM HCQ. Hot and cold colors indicate high and low affinities between ACE2s and RBDs, respectively (scale bar = 10 μm). (b) Time courses of the normalized FRET/CFP ratio of the ACE2 biosensor-WT in HEK293 T cells co-transfected with ACE2-WT (red, n = 4), control (blue-violet, n = 5), or ACE2-M82 K (turquoise, n = 9) treated with 100 μM HCQ. All error bars represent SEM. (***p < 0.001). (c) Time courses of the normalized FRET/CFP ratios of the ACE2 mutant biosensors (E484P-positive control and F486L-negative control) in HEK293 T cells co-transfected with ACE2-WT or ACE2-M82 K treated with 100 μM HCQ (red, blue-violet, and turquoise; n = 5,5, and 4, respectively). All error bars represent SEM (***p < 0.001).
Fig. 3
Fig. 3
Validation of the ACE2 biosensor in response to MLN-4760, a specific ACE2 inhibitor. (a) Time-lapse FRET/CFP ratio images of the ACE2 biosensor in HEK293 T co-transfected with ACE2-WT treated with DMSO, 0.5 nM, and 30 nM MLN-4760, respectively. Hot and cold colors indicate high and low affinities between exogenous ACE2 and RBD, respectively (scale bar = 10 μm). (b) Time courses of the normalized FRET/CFP ratios of the ACE2 biosensor in HEK293 T co-transfected with ACE2-WT treated with DMSO, 0.5 nM, and 30 nM MLN-4760 (gray, blue, and red; n = 4,4, and 7, respectively). All error bars represent SEM (****p < 0.0001).
Fig. 4
Fig. 4
ACE2 biosensor specificity in SY5Y and HepG2 cells. (a-b) Time-lapse CFP, FRET, DIC, and FRET/CFP ratio images of the ACE2 biosensor in SH-SY5Y and HepG2 cells treated with 100 μM HCQ, respectively. Hot and cold colors indicate high and low endogenous ACE2 and RBD affinities, respectively (scale bar = 10 μm). (c) Time courses of the normalized FRET/CFP ratios of the ACE2 biosensor in SH-SY5Y (blue-violet, n = 7) and HepG2 (red, n = 10) cells treated with 100 μM HCQ. All error bars represent SEM (****p < 0.0001).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Li Q., Guan X., Wu P., Wang X., Zhou L., Tong Y., Ren R., Leung K.S.M., Lau E.H.Y., Wong J.Y., Xing X., Xiang N., Wu Y., Li C., Chen Q., Li D., Liu T., Zhao J., Liu M., Tu W., Chen C., Jin L., Yang R., Wang Q., Zhou S., Wang R., Liu H., Luo Y., Liu Y., Shao G., Li H., Tao Z., Yang Y., Deng Z., Liu B., Ma Z., Zhang Y., Shi G., Lam T.T.Y., Wu J.T., Gao G.F., Cowling B.J., Yang B., Leung G.M., Feng Z. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N. Engl. J. Med. 2020 doi: 10.1056/NEJMoa2001316. - DOI - PMC - PubMed
    1. Wu F., Zhao S., Yu B., Chen Y.M., Wang W., Song Z.G., Hu Y., Tao Z.W., Tian J.H., Pei Y.Y., Yuan M.L., Zhang Y.L., Dai F.H., Liu Y., Wang Q.M., Zheng J.J., Xu L., Holmes E.C., Zhang Y.Z. A new coronavirus associated with human respiratory disease in China. Nature. 2020 doi: 10.1038/s41586-020-2008-3. - DOI - PMC - PubMed
    1. Li Y., Wang M., Zhou Y., Chang J., Xian Y., Mao L., Hong C., Chen S., Wang Y., Wang H., Li M., Jin H., Hu B. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. SSRN Electron. J. 2020 doi: 10.2139/ssrn.3550025. - DOI - PMC - PubMed
    1. Chen L., Li X., Chen M., Feng Y., Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc. Res. 2020 doi: 10.1093/cvr/cvaa078. - DOI - PMC - PubMed
    1. Xu X., Yu C., Qu J., Zhang L., Jiang S., Huang D., Chen B., Zhang Z., Guan W., Ling Z., Jiang R., Hu T., Ding Y., Lin L., Gan Q., Luo L., Tang X., Liu J. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. Eur. J. Nucl. Med. Mol. Imaging. 2020 doi: 10.1007/s00259-020-04735-9. - DOI - PMC - PubMed